Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business ...

A $27.2 million one-time non-cash gain was recorded in Q4 2025 following the final sale of Erivedge rights to Oberland.

Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript March 19, 2026 Curis, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.436. Operator: Good afternoon, ...

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused ...

Curis Inc (CRIS) reports a significant quarterly profit, strategic advancements in clinical trials, and a solid financial outlook despite annual losses.

Curis, a biotechnology company dedicated to delivering innovative cancer treatments, has made significant strides in its mission to improve the lives of patients with lymphoma and leukemia. In their ...